Tracon Pharmaceuticals Stock Debt To Equity
| TCONDelisted Stock | USD 1.60 0.55 52.38% |
TRACON Pharmaceuticals fundamentals help investors to digest information that contributes to TRACON Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of TRACON Stock. The fundamental analysis module provides a way to measure TRACON Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TRACON Pharmaceuticals stock.
TRACON |
TRACON Pharmaceuticals Company Debt To Equity Analysis
TRACON Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current TRACON Pharmaceuticals Debt To Equity | 0.35 % |
Most of TRACON Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TRACON Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, TRACON Pharmaceuticals has a Debt To Equity of 0.354%. This is 99.34% lower than that of the Biotechnology sector and 98.17% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.27% higher than that of the company.
TRACON Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TRACON Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TRACON Pharmaceuticals could also be used in its relative valuation, which is a method of valuing TRACON Pharmaceuticals by comparing valuation metrics of similar companies.TRACON Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
TRACON Fundamentals
| Return On Equity | -12.77 | ||||
| Return On Asset | -0.2 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | (32.12) % | ||||
| Current Valuation | (2.64 M) | ||||
| Shares Outstanding | 2.68 M | ||||
| Shares Owned By Insiders | 2.20 % | ||||
| Shares Owned By Institutions | 11.42 % | ||||
| Number Of Shares Shorted | 166.13 K | ||||
| Price To Earning | (1.51) X | ||||
| Price To Book | 11.83 X | ||||
| Price To Sales | 0.45 X | ||||
| Revenue | 12.04 M | ||||
| Gross Profit | (13.89 M) | ||||
| EBITDA | (6.88 M) | ||||
| Net Income | (3.59 M) | ||||
| Cash And Equivalents | 13.58 M | ||||
| Cash Per Share | 0.63 X | ||||
| Total Debt | 968 K | ||||
| Debt To Equity | 0.35 % | ||||
| Current Ratio | 1.17 X | ||||
| Book Value Per Share | (0.66) X | ||||
| Cash Flow From Operations | 3.68 M | ||||
| Short Ratio | 0.95 X | ||||
| Earnings Per Share | 106.40 X | ||||
| Target Price | 30.5 | ||||
| Number Of Employees | 17 | ||||
| Beta | 1.24 | ||||
| Market Capitalization | 3.83 M | ||||
| Total Asset | 10.11 M | ||||
| Retained Earnings | (240.5 M) | ||||
| Working Capital | (1.09 M) | ||||
| Current Asset | 53.31 M | ||||
| Current Liabilities | 14.18 M | ||||
| Net Asset | 10.11 M |
About TRACON Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TRACON Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TRACON Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TRACON Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with TRACON Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TRACON Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TRACON Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with TRACON Stock
Moving against TRACON Stock
| 0.56 | VERA | Vera Therapeutics | PairCorr |
| 0.51 | DMAC | DiaMedica Therapeutics Upward Rally | PairCorr |
| 0.49 | VCYT | Veracyte Buyout Trend | PairCorr |
| 0.48 | DRUG | Bright Minds Biosciences | PairCorr |
| 0.47 | DSGN | Design Therapeutics Upward Rally | PairCorr |
The ability to find closely correlated positions to TRACON Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TRACON Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TRACON Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TRACON Pharmaceuticals to buy it.
The correlation of TRACON Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TRACON Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TRACON Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TRACON Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in TRACON Stock
If you are still planning to invest in TRACON Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the TRACON Pharmaceuticals' history and understand the potential risks before investing.
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |